Background: Previous analyses concerning health components of European Union (EU)-funded research have shown low project participation levels of the 12 newest member states (EU-12). Additionally, there has been a lack of subject-area analysis. In the Health Research for Europe project, we screened all projects of the EU's Framework Programmes for research FP5 and FP6 (1998-2006) to identify health research projects and describe participation by country and subject area. Methods: FP5 and FP6 project databases were acquired and screened by coders to identify health-related projects, which were then categorized according to the 47 divisions of the EU Health Portal (N = 2728 projects) plus an extra group of 'basic/biotech' projects (N = 1743). Country participation and coordination rates for projects were also analyzed. Results: Approximately 20% of the 26 946 projects (value E29.2bn) were health-related (N = 4756. Value E6.04bn). Within the health categories, the largest expenditures were cancer (11.9%), 'other' (i.e. not mental health or cardiovascular) non-communicable diseases (9.5%) and food safety (9.4%). One hundred thirty-two countries participated in these projects. Of the 27 EU countries (and five partner countries), north-western and Nordic states acquired more projects per capita. The UK led coordination with > 20% of projects. EU-12 countries were generally under-represented for participation and coordination. Conclusions: Combining our findings with the associated literature, we comment on drivers determining distribution of participation and funds across countries and subject areas. Additionally, we discuss changes needed in the core EU projects database to provide greater transparency, data exploitation and return on investment in health research.
or E55bn according to other official sources) 3 under FP7. Despite the current austerity drive, the European Commission (EC) has proposed to increase science funding to E80 billion 4 (although recently revised to around E70bn) 5 for the next 7-year programme called 'Horizon 2020', which will run from 2014 to 2020. 6 As the Framework Programmes have emphasized integration of research between countries (and globally), concerns have grown that the scheme is over-complicated and bureaucratic. 7 Despite these problems, it is argued that the return on investment is considerable, with claims of a community contribution of E7 billion/year to scientific research potentially generating an increase in EU Gross Domestic Product (GDP) of E200 billion/year by the 2030s. 8 In preparation for the Horizon 2020 Programme, the EU Commission has prioritized science and technology as a means to secure Europe's economic future and has committed to reduce bureaucratic load on participants while enhancing the exploitation of scientific knowledge and innovative/technology developments within its programmes. 6 Expenditure on research is most productive when its results can be harnessed by future researchers, healthcare professionals, businesses and policymakers. 9, 10 In the Health Research for Europe Project, 11 we have explored the utility of the EU's database of FP5 and FP6 projects for mapping the nature of health research funding and tracking its outputs. We found that >50% of 3691 health-related research projects funded by the EU (only 3691 of the set of 4756 projects had alphanumeric grant codes suitable for Web mining) did not produce any academic output traceable through Google Scholar and PubMed. 12 Although the larger projects were more productive (for projects funded >E1.45 M, 84% had at least one traceable PubMed article), the overall '50%' result was not unexpected, given findings that only 53% of research reported in conference abstracts is published as full reports 13 and approximately half of clinical trials go unpublished. 14, 15 Given also our previous unsuccessful attempts, despite intensive effort, to map wider indicators of productivity of EU-funded health-related research using questionnaires to project leaders, 16, 17 we have made a series of recommendations for the EU to revise the recording and disseminating of the science it funds.
12,16-18
Here we focus not on the outputs, but rather on the funding entering into health-related research under the EU's Framework 5 and 6 competitive research programmes. Although some reports and assessments commissioned by the EU or government bodies are available concerning distribution of funds across countries, there has been a dearth of analysis or discussion within the peerreviewed academic literature. Reports have shown that participation of the 12 newest member states (EU-12) in the Framework programmes is low across the board, 19, 20 but particularly notable for health-related research. 19 Financial contributions to these EU-12 countries and their incidences of coordinating projects are even lower. 20 We explored these areas within our own database derived from screening all FP5 and FP6 projects to identify and then classify those that had an endpoint in improving human health. We then analyzed those projects by participation and coordination across countries, using denominators such as country population and GDP alongside indicators of country-level scientific investment, capacity and output to place those results in context. Identifying key correlates can help set hypotheses for improving rates of success.
The structure of funding is also detailed by project size and subject-area classification. The latter was entirely lacking in the FP5 and FP6 databases beyond vague funding line information. Breaking down funding by subject area not only provides transparency on investment so far (allowing comparisons with research priorities or economic burdens of diseases), but we predict that it will be important to integrate to EU projects databases in the future for purposes of research mapping. Thus, this first effort provides a useful starting point for improved recording in the future.
Methods
We requested from the EC, the entire database of all EU projects funded under FP5 and FP6, numbering 26 946 projects, which was transferred to us from the 'European Data Warehouse' in December 2007 on CD-ROM in Microsoft Access format (FP5 and FP6 as separate files). Information in the two databases included project ID, title, abstract, start and end dates, fund, contract type, coordinator and participant countries, participating institutes (by name, unstandardized) and project coordinator contact information (often incomplete). 17 Following agreement on definitions and piloting, all projects were classified as being human 'health-related' (N = 4756) or 'not healthrelated' (N = 22 190) by a team of >10 PhD-level coders (inter-rater reliability of two coders rating a sample of 200 projects: kappa = 0.88). 16 This coding was to capture health-related projects outside health funding lines [e.g. relevant information and communications technology (ICT) projects]. Animal studies were included if the focus was human health, not veterinary research. The nominated health-related projects were then confirmed and classified by a team of six full-time project staff. Conferences (N = 285) were excluded because they were not 'research' projects. Biotech/basic science projects (N = 1743) were labelled 'biotech' and not categorized further when they related to underpinning research, rather than any specific treatment (e.g. vaccinations) or disease. The remaining projects (N = 2728) were categorized into the 47 categories used on the EU Health Portal. 21 Some categories were further sub-classified, where appropriate. The categories of the Health Portal were chosen as a system due to the original purpose of the project, which was to produce summaries of research undertaken for these categories for use by the portal itself.
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Regarding project participation breakdown by country, we chose several key country statistics (all for year 2007, where possible, to maximize both data completeness and proximity in time to the research activity) to allow calculation of, or serve independently as, denominators and correlates for our data on project participation and coordination rates. Those external data were country population according to Eurostat, 22 25 and academic output (scientific and technical journal articles). 26 To fit our results with similar reports, 27 we divide country participation into EU-15 countries (the original 15 member states), EU-12 (the 12 newest member states: Bulgaria, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia) and associated countries (Israel plus the European Free Trade Association States-EFTA: Iceland, Liechtenstein, Norway and Switzerland). Note that 'EU-12' used to refer to the original 12 EU, but now is used by the EC to refer to the 12 newest members (10 of which joined in 2004 and 2 in 2007-so were not full members during all the time of study). EC EU-27 national contributions to the EU budget in 2007 can be found elsewhere 28 ; EFTA countries contribute to the EU science budget according to their GDP and Israel also contributes funds. 29 'Rest of world' participation is cited in other reports, so it is given here where appropriate.
Data management used Microsoft Access and Microsoft Excel. Summary statistics, analyses and graph generation were run in Microsoft Excel and IBM SPSS Statistics version 21 (licensed to University College London).
Results
From the full database of 26 946 projects, 4756 were identified as relating to human health (hereafter labelled 'health-related'). Collectively, these were funded to a value of E6.037 billion and represent 12 212 years of research (project months, not person months). A total of 2662 projects (E2.00bn, 6663 funded years, average project cost = E753 K) were from FP5 and 2094 projects (E4.03bn, 5549 years, average cost = E1.926 million/project) were from FP6.
The total sum identified in the full database amounted to E29.91 billion (E13.41bn under FP5 and E16.50bn under FP6). This stands in contrast to the expected E34.073 billion: namely, E14.96 billion (E13.7bn + E1.26bn for Euratom) officially declared for FP5 30 and E19.113bn (E17.883bn + E1.23bn for Euratom) officially declared for FP6. 1 Note that this unresolved discrepancy is discussed elsewhere. 12 One hundred and thirty-two countries/territories worldwide participated in at least one FP5 or FP6 health-related project. Table 1 shows the 27 EU countries plus 5 associated countries alongside the number of projects in which they participated and which they led. Population and GDP are presented alongside these data, as are proportion of GDP spent on research, researcher base (number of researchers per million people) and total national science and technology publications (all for 2007, where possible; see Methods for origins of these data).
As population size strongly predicts total project participation (Pearson's r = 0.90, N = 32, P < 0.001), rates of project participation and coordination per capita were compared with indicators of financial and scientific capacity per capita to identify the closest associates with success rates of engagement in EU-funded healthrelated research. Correlations were as follows for participation rate per million inhabitants: GDP/pop (r = 0.51, N = 32, P = 0.003), R&D researchers/pop (r = 0.60, N = 30, P = 0.001), total R&D expenditure/ pop (r = 0.76, N = 31, P < 0.001) and S&T papers/pop (r = 0.79, N = 31, P < 0.001). A similar pattern was seen for projects coordinated per million inhabitants: GDP/pop (r = 0.46, N = 32, P = 0.008), R&D researchers/pop (r = .71, N = 30, P < 0.001), total R&D expenditure/pop (r = 0.69, N = 31, P < 0.001) and S&T papers/pop (r = 0.74, N = 31, P < 0.001).
Many relationships derived from the data in table 1 could be plotted to get clearer pictures of country success rates in EU health project participation or coordination and their relationships with other dimensions. In figure 1 , we have chosen to show the relationship between health project participation (FP5 and FP6 combined) per million people and the number of R&D researchers (note: all science) per million people. Figure 2 shows the entire categorization process from the original 26 946 FP5 and FP6 projects down to the 47 categories of the EU Health Portal 21 (N = 2728) and the large 'basic/biotechnology' category (N = 1743), which contains many projects in the areas of intracellular molecular interactions, signalling, stem-cell research, 'ageing' (from the cellular perspective), DNA interactions and genomics. These categories cover disease categories and other health-related topics. The largest category of non-biotechnology projects was cancer, accounting for >12% of all projects. Numbers of projects and associated funds for categories not shown in the figure 2 pie-chart are given in the legend. A few categories were further disaggregated. Figure 2 also shows a sub-categorization of mental health, where projects studying Alzheimer's disease received over twice as much money (>E35 m: 29 projects) as the next largest category, depression.
The largest total increases between FP5 and FP6 were basic/biotechnology (up E820.9 m, 266% of FP5 level), cancer (E214.8 m, 254%), food safety (E212.2 m, 340%) and medicines and treatment (E114.4 m, 189%). The category showing the largest decrease was elderly (E36.8 m, 58% of FP5 level).
To describe patterns of project finance/structure, the projects were divided into 10 financial bands (table 2) . Whereas projects with a value of less than E80 K lasted, on average, 12.2 or 18.8 months (FP5 and FP6, respectively) and received, on average, E2.8 K or E3.4 K EUR/month (FP5 and FP6, respectively), projects more than E4 million lasted, on average, 48.2 or 52.3 months (FP5 and FP6, respectively) and received, on average, E135.9 K or E188.5 K EUR/ month (FP5 and FP6, respectively) . Most other projects range from 24 to 40 months in duration. The mean number of participating institutes jumps sharply (1.7-7.1 in FP5: 1.3-5.7 in FP6) at the E240 K funding boundary, indicating a preponderance of large multi-centre projects above this point.
Attempts to break down projects by participating entity indicated that many leading institutes went by more than one name. (This has now been fixed for FP7, as institutes have been given ID numbers). Similarly, attempts to analyze by grant type were limited due to only 61% completeness for grant type data in the database provided.
Discussion
Screening all 26 946 FP5 and FP6 research projects showed that $20% of the total EU funding under these research programmes had been allocated to projects that are aimed at improving human health. This is an important finding because although allocations to official health research lines have been declared (17.6% of the total budget under FP5, 14.0% in FP6 and 12.0% in FP7 up to 2010), it has also been stated that the total investment in health (which may include projects from other components such as ICT) was unknown. 27 This allocation could certainly increase further, as the same report notes that the US, Japan, Australia and some EU member states allocate 35-50% of total research funds to health research.
As seen in other assessments of EU-funded projects (and healthrelated projects in particular), 20, 27 EU-12 countries performed poorly compared with EU-15 and associated countries; the noted exceptions in our analyses being Estonia, Cyprus and Slovenia. In terms of predictors of success in project participation and coordination, GDP per capita was seen to be a weaker correlate than researcher base, scientific investment and scientific output. Interestingly, the last of these was the best predictor of both participation and coordination rates, indicating perhaps that engagement in the global scientific community is a key factor in success. Small EU-15 countries appear to acquire more project participation than their larger counterparts with similar researcher bases. We note that it would be productive to investigate whether small nations are more dependent on EU fund/multinational collaborations to run larger projects, but we do not have opportunity to incorporate relevant information and analysis here.
The actual financial amounts allocated to the participating countries were not included in the database. However, these data appear to be available (at least for FP6 and FP7), as the EC has reported them in the Impact Assessment on health research funding. 27 In that report, a 6.2% participation rate for EU-12 under FP6 LifeSciHealth was associated with 3.0% of the financial contribution. Similarly, the 5.8% EU-12 participation rate under FP7 Health (up to 2010) was associated with 2.5% of the financial contribution. Compare this with EU-15 participation rates of 83.3 and 78.1%, associated with budget shares of 88.4 and 85.0%. As we have highlighted previously, 18 the EU-12 participation-to-fund ratio reported in this Impact Assessment is even lower than that for the 'rest of world' category, which includes many developing countries.
How has this issue of EU-12 under-representation been addressed in the associated reports and investigations? The Impact Assessment itself makes little commentary on it. The extensive Horizon 2020 official documentation does not express overt concern nor plan of action on these fronts. 6 A report on new member state participation in FP7, commissioned by the German Federal Ministry of Education and Research, notes that the large discrepancy is due to markedly lower salary rates in those countries, then proceeds only to conclude that therefore participation rates better indicate engagement than funding rates. 20 A common position paper of the EU-12 member states 31 also notes the issue and therefore encourages project selection to include criteria of value for money, alongside recommendations of lowering bureaucracy and balancing a need for competitiveness with benefits of EU-12 integration. Although we agree that reducing bureaucracy and stimulating integration will be of substantial help to EU-12 countries, we disagree with the 'value for money' considerations. Even if the EU-12 acquire more projects, we believe they will continue to lose their best brains to Western Europe and elsewhere if their young scientists are paid substantially lower salaries. Even Slovenia, which appears to perform well in analyses of participation, faces continual brain drain due to harsh local salaries, and these are the rates that the EU copies for reimbursement. This is why we argue for equal pay for equal work, pulling compensation in line with participation, so that EU-12 can regain its competitiveness. Elsewhere, we describe the potential positive knock-on effects of making such a change.
18 Figure 1 The relationship between national researcher base (all science) and success rates of participating in EU-funded health-related research. Circle sizes (areas) approximate country populations. Grey circles denote EU-15 countries, black circles denote EU-12 countries and white circles denote associated countries. Excluded are Israel and Liechtenstein, for which no researcher base data were available Turning to subject areas, mapping health research in Europe is an increasingly important area. The plans for Horizon 2020 explicitly include better mapping and monitoring (see Section 6: Evaluation and Monitoring of the Impact Assessment accompanying the Horizon 2020 communication from the Commission). 32 In addition, there have been recent calls for research projects to cover such areas. Our choice of the EU Health Portal's 47 categories for subject mapping was based on the original aim of the project, which 285 Conferences: €74m (Those projects that could be categorised according to the 47 categories of the EU Health Portal. Basic/biotech projects with no specific disease focus were excluded. As were conferences.) (8) Brain processes (27) Brain damage /stroke (8) Stress (6) Parkinson's Disease (21) Programmes/ PromoƟon (14) Depression ( Other (30) Other neurodegeneraƟon (6) Prion diseases (7) Expenditure (Millions of Euros) Figure 2 The breakdown of all FP5 and FP6 research projects into health-related research categories. Note that of the total 26 946 projects, 117 FP5 projects and 6 FP6 projects had missing financial data. These numbers are reduced to 23 and 1, respectively, when the 4756 healthrelated projects are considered. The category of 'Programmes' in the pie-chart was generally used for training, networking, information pooling and other such capacity-building programmes. had been to identify and showcase the 'best' research in these areas. 16, 17 However, as the study progressed and feedback from many project leaders was not forthcoming, the research direction turned more to economic analysis. The classification system used here clearly has many limitations, including arbitrary decisions (e.g. 'HIV/AIDS' or 'Vaccinations' for many projects developing HIV vaccines), poorly represented categories and the basic/biotechnology 'bin', which clearly needs to be unpacked in a meaningful way. This would be ideal, as the system includes dimensions of health area and also research level. The latter is important because a recent analysis of UK health research by the UK Clinical Research Collaboration highlighted imbalances and identified nearly 60% of total spend went either to 'underpinning' or 'aetiology', with only 3.7% on 'prevention' and 3.2% on 'disease management'. Adopting a common system also allows identification of overlaps and gaps across funders. We hope this call by the European Medical Research Council means that this classification will be integrated into the EU's central (CORDA) database for health-related projects Horizon 2020. In addition, with so many competent bodies now providing online graphical analysis interfaces to their core databases, our suggestion is that the EU's Directorate General for Research and Innovation at least follow suit. They could usefully look to the US National Institutes of Health RePORTER system 34 for innovations in disseminating the metadata on funded health-related research.
Research area (number of projects)
Transparency offers the opportunity for scientists to engage in policy discussion and to critique funding priorities. This opens to a wider audience the question of whether funding should be driven by economic burden of disease, potential for cost-effective treatment, the number of researchers interested in the area, patient group lobbying or other factors. Previous research has found little association with the economic burden of disease [35] [36] [37] or, in some cases, patient need. 38 Presenting such data also helps the public, clinicians and patient bodies to engage in the debate. To this end, we applaud the EU's commitment under the Horizon 2020 programme to harness researchers to solve critical issues of social need. 6 However, 'bottom-up' research is also an important channel of innovation and so a balance is needed.
Our call for better mapping fundamentally requires better informatics at the heart of EU research coordination (i.e. the CORDA/E-CORDA databases). Related to this, we have previously stated that the EU should look to make automated links between its projects and their outputs in the same way the American NIH link their projects to PubMed. 12 We also recommended that the EU should take the bold step to demand that databases generated by projects are shared as a project 'deliverable' via a central searchable EU repository. 12, 18 The EU's own OpenAIRE project 39 could easily serve as such an interface, even when databases are housed in different locations, such as with Figshare (www.figshare.com). Not only does central vetting and publishing of databases allow fuller exploitation of data collection funded by the EU taxpayer, it also helps tackle science-wide issues of 'file-drawer' problems and selective publishing that can distort the big-picture scientific knowledge profoundly.
In conclusion, although there has been much criticism of the centralized EU science funding scheme in the past, the new vision of a simplified single funding programme for EU-level science is looking promising. However, there remain needs for further bureaucracy reduction, better research mapping and literature informatics linking, greater transparency, centralized open data initiatives and more equitable pay across member states. 
